Search research articles

关于 JoVE

概览领导团队博客 JoVE 帮助中心

作者

出版流程编辑委员会范围与政策同行评审常见问题投稿

图书馆员

用户评价订阅访问资源图书馆顾问委员会常见问题

研究

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments 存档

教育

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual 教师资源中心教师网站

使用条款与条件

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序

Same author

KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion.

Apoptosis : an international journal on programmed cell death·2026

Same author

Supernatant: What's in a name?

Cancer cytopathology·2026

Same author

Next-generation sequencing using a targeted gene panel in advanced solid tumors: five years of experience from an Italian referral institution.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

Same author

Analytical reliability of cell-free DNA from fine-needle aspiration rinses for BRAF and NRAS testing in metastatic melanoma.

Journal of the American Society of Cytopathology·2026

Same author

FKBP5 isoforms shape immune pathways related to tumor tolerance.

Cell death discovery·2026

Same author

Cellularity of Routinely Prepared Cell Blocks: Insights From an International Study.

Cytopathology : official journal of the British Society for Clinical Cytology·2026

Search research articles

相关实验视频

Updated: May 16, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

肺细胞学中的PD-L1:标准化的道路

Mohammed S I Mansour, Gennaro Acanfora, Giancarlo Troncone

Acta cytologica

|May 14, 2025

概括

在细胞学中通过免疫组织化学 (IHC) 评估编程死亡配体1 (PD-L1) 是复杂的. 本次审查强调了验证,质量控制和观察者间变异性方面的挑战,以准确地做出肺癌治疗决定.

科学领域:

在瘤学瘤学.
病理学病理学病理学
免疫组织化学免疫组织化学

背景情况:

编程死亡-1 (PD-1) /PD-L1抑制剂已经改变了肺癌治疗.
准确的PD-L1免疫组织化学 (IHC) 评估对于治疗选择至关重要.
与组织学样本相比,在细胞学样本上进行PD-L1测试存在重大挑战.

研究的目的:

在细胞学样本中审查和解决PD-L1 IHC测试的复杂性.
专注于验证准则,质量评估,细胞组织学相关性和观察者之间的变异性.
综合当前的指导方针和研究,以便在细胞学中可靠地评估PD-L1.

主要方法:

审查当前的指导方针,特别是来自美国病理学家学院 (CAP).
分析了48篇关于PD-L1表达的细胞组织学一致性的原始文章.
讨论质量评估中的挑战和细胞学样本中观察者间的变异性.

主要成果:

最近的CAP指南强调对非正式固定标本进行严格的验证.
对于PD-L1表达的细胞组织学一致性显示出显著的变异性 (1%切断时为54-100%,50%切断时为82-100%).
在1-49%的PD-L1表达范围内,观察者间的变异性尤其显著.

更多相关视频

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Published on: May 9, 2018

相关实验视频

Last Updated: May 16, 2025

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Published on: May 9, 2018

结论:

细胞学中的PD-L1测试在验证,质量控制和观察者间协议方面面临障碍.
标准化的指导方针和彻底的验证对于在细胞学样本中准确评估PD-L1至关重要.
解决这些挑战对于优化肺癌患者免疫治疗至关重要.